Work

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

Year: 2012
Type: review
Abstract: In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,790
Funder: Pfizer
OpenAlex ID: W2077409585
FWCI: 5.076
Cites: 65
Cited by: 241
Related to: 9